TOP2A was associated with a decreased time to metastatic disease (HR 4.13; p = 0.044), decreased DSS (HR 3.51; p = 0.014), and decreased OS (HR 2.65; p = 0.012). The gene discussed is TOP2A; the disease is metastatic neoplasm.